我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

磷酸肌酸钠治疗扩张型心肌病心功能不全的疗效观察

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
689-691
栏目:
临床研究
出版日期:
2013-11-25

文章信息/Info

Title:
Effect of sodium phosphocreatine on patients with dilated cardiomyopathy with heart failure
作者:
李鹏飞1; 冷 飞2
(葫芦岛市中心医院：1.循环一科，2.内分泌科，辽宁 葫芦岛 125001)
Author(s):
LI Peng fei1;  LENG Fei2
(1.Department of Cardiovasology, 2.Department of Endocrinology, Huludao Central Hospital, Huludao 125001, Liaoning, China)
关键词:
磷酸肌酸钠; 扩张型心肌病; 心功能不全; 脑钠尿肽
Keywords:
sodium phosphocreatine;  dilated cardiomyopathy;  heart failure;  probrain natriuretic peptide
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的:观察磷酸肌酸钠治疗扩张型心肌病伴心功能不全患者的疗效。方法:将103例扩张型心肌病心功能不全的患者随机为两组，对照组给予血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂，利尿剂，β受体阻滞剂（无禁忌证），强心剂,血管扩张剂等基础抗心衰治疗，试药组在此基础上给予磷酸肌酸钠。观察治疗前和治疗后患者的心功能分级、左室收缩功能相关参数的变化，并观察药物不良反应。结果:两组患者经治疗后临床症状均有好转，但是试药组心悸、呼吸困难、水肿等改善率，脑钠尿肽水平的下降、左室射血分数的增加显著优于对照组（P<0.05）。结论:磷酸肌酸钠可以安全、有效地改善扩张型心肌病心功能不全患者的临床症状和心功能指标。
Abstract:
AIM:To explore the possible mechanism and to evaluate the clinical effects of sodium phosphocreatine in patients with dilated cardiomyopathy (DCM) with heart failure. METHODS: A cohort of 103 cases with DCM with heart failure was randomized into two groups. The control group was given ACEI or AEB agents, diuretics, β blockers (without contraindications), cardiac stimulant, and vasodilator agentbased anticardiac insufficiency treatment, whereas the therapy group was administered the same regimen plus sodium phosphocreatine. Changes in functional heart classifications and left ventricular diastolic function parameters and adverse drug reactions were observed before and after treatment. RESULTS: Clinical symptoms in both groups were alleviated after treatment, but clinical symptoms and signs such as shortness of breath, palpitations, and edema in the therapy group were better improved than in the control group (P<005). The decrease in probrain natriuretic peptide (BNP) levels and increase in left ventricular ejection scores in the therapy group were also more obvious (P<0.05). CONCLUSION: Sodium phosphocreatine can safely and effectively alleviate clinical symptoms and improve cardiac functions in patients with dilated cardiomyopathy with cardiac insufficiency.

参考文献/References

[1]Caforio AL,Tona F,Bottaro S,et al.Clinical implicationsof antiheart autoantibodies in myocarditis and dilated cardiomyopathy[J].Autoimmunity,2008,41(1):35-45.
[2]Lappe JM,Pelfrey CM,Tang WH.Recent insights into therole of autoimmunity in idiopathic dilated cardiomyopathy[J].J Card Fail,2008,14(27):521-530.
[3]Jahns R,Boivin V,Schwarzbach V,et al.Pathological autoantibodies in cardiomyopathy[J].Autoimmunity,2008,41(6):454-461.
[4]Pitt B,PooleWilson PA,Segal R,et al.Effect of losartan versus captopril in patients with sympto matic heart failure:randomized trial the Losartan Heart Failure Survival Study ELITE Ⅱ[J]. Lanect,2000,355(9241):1582-1587.
[5]Cazeau S,Leclercq C,Lavergne T,et al.Effects of multisitc biventricular pacing in patients with heart failure and intraventricular conduction delay[J].N Engl J Med,2001,344( 22):873-880.
[6]Komamura K,Tatsumi R,Miyazaki J,et al. Treatment of dilatedcardiomyopathy with electro poration of hepatocyte growth factorgene into skeletal muscle[J].Hypertension,2004,44(3):365-371.
[7]Bax JJ,Abranham T,Barold SS,et al.Cardiac resynchronization therapy:part 1issues before device implantation[J].J Am Coll Cardiol, 2005,46(12):2153-2167.

备注/Memo

备注/Memo:
收稿日期：2013-01-15.作者简介：李鹏飞，主治医师Email:sanpang0219@126.com
更新日期/Last Update: 2013-11-20